CollPlant (CLGN) Biotechnologies announced that the European Patent and Trademark Office has allowed a patent application related to CollPlant’s injectable fillers and regenerative breast implant candidates, being developed for the aesthetic and reconstructive procedures markets, respectively. This newly allowed patent application pertains to CollPlant’s injectable soft tissue fillers as well as its organ manufacturing technology related to its regenerative breast implant pipeline currently under development. The European Patent Application is directed, among other things, to a 3D biocompatible and degradable soft tissue implant composed of a bioprinted scaffold and an injectable filler within it, each based on its recombinant human collagen.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLGN:
- CollPlant Biotechnologies Announces $3.6 Million Securities Offering
- CollPlant Biotechnologies Secures $3.6 Million in Direct Offering
- CollPlant to sell 1.2M ordinary shares at $3.00 in registered direct offering
- CollPlant Biotechnologies Reports Strong Q1 2025 Results
- CollPlant Biotechnologies Announces Q1 2025 Financial Results and Corporate Progress
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue